Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ: ABOS · IEX Real-Time Price · USD

3.190

+0.010 (0.31%)

At close: Apr 25, 2024, 4:00 PM

3.230

+0.040 (1.25%)

After-hours: Apr 25, 2024, 6:17 PM EDT

Acumen Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	18.82	12.88	7.28	1.35	0.93
Research & Development	42.32	32.36	12.31	8	8.58
Operating Expenses	61.14	45.24	19.58	9.35	9.5
Operating Income	-61.14	-45.24	-19.58	-9.35	-9.5
Interest Expense / Income	0.58	0	0	0	0
Other Expense / Income	-9.35	-2.38	81.02	-2.02	-1.6
Pretax Income	-52.37	-42.86	-100.61	-7.33	-7.91
Net Income	-52.37	-42.86	-100.61	-7.33	-7.91
Preferred Dividends	0	0	0	0	-0.22
Net Income Common	-52.37	-42.86	-100.61	-7.33	-7.69
Shares Outstanding (Basic)	49	41	20	0	0
Shares Outstanding (Diluted)	49	41	20	0	0
Shares Change	19.72%	102.43%	4685.58%	-2.71%	-
EPS (Basic)	-1.08	-1.06	-5.02	-17.48	-17.84
EPS (Diluted)	-1.08	-1.06	-5.02	-17.48	-17.84
Free Cash Flow	-43.08	-35.31	-18	-7.45	-6.82
Free Cash Flow Per Share	-0.89	-0.87	-0.90	-17.77	-15.83
EBITDA	-51.61	-42.69	-100.6	-7.33	-7.91
Depreciation & Amortization	0.18	0.17	0	0	0
EBIT	-51.79	-42.86	-100.61	-7.33	-7.91

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).